Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
解锁市场时间线与信号动态
该公司进入各个市场的顺序 — 从最早到最新
治疗慢性阻塞性肺病新药申请获中国受理
治疗慢性阻塞性肺病新药申请获中国受理
注册以查看完整信号动态
Verona Pharma 的国际扩张与竞争对手的对比情况
Verona Pharma你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Verona Pharma你 | 0 | 0 | 0% | 0 | 18 |
Medical Science Liaison
查看职位California, United States · 去年
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
Nuance Pharma 的第三期 ENHANCE-CHINA 试验评估雾化恩西芬特林治疗 COPD，达到主要和次要终点，显示显著改善肺功能和降低急性加重率。
优锐医药的ENHANCE-CHINA试验显示恩司芬群在COPD治疗中显著改善肺功能、生活质量，并降低急性加重风险。计划2025年下半年提交新药申请。
优锐医药的ENHANCE-CHINA试验显示恩司芬群在COPD治疗中显著改善肺功能、生活质量，并降低急性加重风险。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Verona Pharma 的业务、市场和增长信号的快速解答。
